Page 2 - Sam Eiber News Today

AtriCure (NYSE: ATRC) shares dipped today despite fourth-quarter results that came in ahead of the consensus forecast.

Abbott (NYSE: ABT) announced today that an FDA advisory committee ruled that the benefits of its TriClip outweigh the risks.

Edwards Lifesciences (NYSE: EW) shares dipped slightly today on fourth-quarter results that topped the consensus sales forecast.

Edwards Lifesciences (NYSE:EW) announced today that the FDA granted approval for its Evoque tricuspid valve replacement system.

Bloomberg reports that a court declined to grant a longer pause on the Apple Watch import ban as a result of patent litigation with Masimo.

Medical device giant Boston Scientific added to its string of recent acquisitions by announcing its plan to buy Axonics, a maker of neurostimulation devices that treat urinary and bowel dysfunction, for $3.7 billion. Experts agree that this deal will make a profitable impact on Boston Scientific’s urology business.

Boston Scientific announced today that it agreed to acquire Axonics in a deal worth approximately $3.7 billion.

The FDA today published a 510(k) premarket notification granting clearance to the Stork baby monitoring system from Masimo.

Apple reportedly paused sales of two models of its smartwatches in the U.S. as it looks to resolve a patent dispute with Masimo.

BTIG analysts say a small survey of surgeons may indicate an oversell of AtriCure stock following Medtronic's launch of a competing device.